Dicerna Pharmaceuticals (DRNA) Downgraded by BidaskClub to “Hold”

Share on StockTwits

BidaskClub downgraded shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) from a buy rating to a hold rating in a research report report published on Friday, June 8th.

Several other research firms also recently commented on DRNA. HC Wainwright reaffirmed a hold rating and issued a $14.00 price target on shares of Dicerna Pharmaceuticals in a research note on Tuesday, May 15th. Evercore ISI reaffirmed an outperform rating and issued a $17.00 price target (up previously from $14.00) on shares of Dicerna Pharmaceuticals in a research note on Friday, April 20th. ValuEngine raised shares of Dicerna Pharmaceuticals from a buy rating to a strong-buy rating in a research note on Wednesday, May 2nd. Chardan Capital began coverage on shares of Dicerna Pharmaceuticals in a research report on Friday, March 9th. They set a neutral rating on the stock. Finally, Stifel Nicolaus raised their target price on shares of Dicerna Pharmaceuticals from $10.00 to $17.00 and gave the company a buy rating in a research report on Friday, March 9th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. Dicerna Pharmaceuticals presently has a consensus rating of Buy and an average price target of $12.88.

Shares of Dicerna Pharmaceuticals opened at $13.65 on Friday, according to MarketBeat Ratings. Dicerna Pharmaceuticals has a 1 year low of $2.69 and a 1 year high of $15.80. The firm has a market capitalization of $690.91 million, a PE ratio of -3.73 and a beta of 2.34.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its earnings results on Monday, May 14th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.87) by $0.57. Dicerna Pharmaceuticals had a negative net margin of 1,665.11% and a negative return on equity of 123.72%. The firm had revenue of $1.55 million during the quarter, compared to analyst estimates of $1.75 million. research analysts anticipate that Dicerna Pharmaceuticals will post -1.35 EPS for the current year.

In other Dicerna Pharmaceuticals news, insider James B. Weissman sold 8,965 shares of Dicerna Pharmaceuticals stock in a transaction that occurred on Friday, April 20th. The shares were sold at an average price of $13.00, for a total transaction of $116,545.00. Following the completion of the sale, the insider now directly owns 9,800 shares in the company, valued at approximately $127,400. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider James B. Weissman sold 10,000 shares of Dicerna Pharmaceuticals stock in a transaction that occurred on Wednesday, May 9th. The shares were sold at an average price of $15.00, for a total transaction of $150,000.00. Following the sale, the insider now owns 19,800 shares of the company’s stock, valued at $297,000. The disclosure for this sale can be found here. 19.85% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in DRNA. Emerald Advisers Inc. PA acquired a new stake in Dicerna Pharmaceuticals during the 4th quarter valued at approximately $266,000. Monashee Investment Management LLC purchased a new position in shares of Dicerna Pharmaceuticals during the 4th quarter valued at approximately $1,878,000. EAM Investors LLC purchased a new position in shares of Dicerna Pharmaceuticals during the 4th quarter valued at approximately $581,000. Renaissance Technologies LLC increased its holdings in shares of Dicerna Pharmaceuticals by 19.3% during the 4th quarter. Renaissance Technologies LLC now owns 560,300 shares of the biopharmaceutical company’s stock valued at $5,060,000 after purchasing an additional 90,700 shares in the last quarter. Finally, RTW Investments LP increased its holdings in shares of Dicerna Pharmaceuticals by 142.2% during the 4th quarter. RTW Investments LP now owns 5,035,662 shares of the biopharmaceutical company’s stock valued at $44,142,000 after purchasing an additional 2,956,671 shares in the last quarter. Institutional investors and hedge funds own 77.28% of the company’s stock.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.

Analyst Recommendations for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply